These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26204323)

  • 1. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.
    Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y
    J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
    Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
    Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
    Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
    Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM.
    Xin C; Ye S; Ming Y; Shenghua Z; Qingfang M; Hongxing G; Xu S; Yuanfu X; Yuan Z; Dongmei F; Juanni L; Yingdai G; Lianfang J; Rongguang S; Zhenping Z; Jianxiang W; Tao C; Chunzheng Y; Dongsheng X; Yongsu Z
    Gene Ther; 2010 Oct; 17(10):1234-43. PubMed ID: 20463754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
    Liu XY; Zhen YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
    Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
    Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
    Shang BY; Shang Y; Zhen YS; Chen SZ
    Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma.
    Fan D; Jiang L; Song Y; Bao S; Yang Y; Yuan X; Zhen Y; Yang M; Xiong D
    Front Oncol; 2019; 9():861. PubMed ID: 31555598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The synergistic effect of lidamycin and rituximab on human B cell lymphoma].
    Sun YR; Zhang SH; Shao RG; He HW
    Yao Xue Xue Bao; 2014 Feb; 49(2):198-203. PubMed ID: 24761609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitory effects of the immunoconjugate composed of anti-type IV collagenase antibody Fab' fragment and lidamycin on tumor invasion and metastasis].
    Feng Y; He HW; Li BW; Zhang ZX; Chen X; Li XF
    Yao Xue Xue Bao; 2011 Dec; 46(12):1462-5. PubMed ID: 22375419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
    Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
    Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
    Sapra P; Moase EH; Ma J; Allen TM
    Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells.
    Cheng WW; Das D; Suresh M; Allen TM
    Biochim Biophys Acta; 2007 Jan; 1768(1):21-9. PubMed ID: 17046711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J; Ouyang ZG; Zhang SH; Zhen YS
    Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lidamycin inhibits the cancer cell PKC activity induced by basic fibroblast growth factor.
    Zhen HY; Huang YH; Zhen YS
    Yao Xue Xue Bao; 2005 Dec; 40(12):1110-5. PubMed ID: 16496675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.